Krishnamurti endorses sickle cell gene therapies for Medicaid patients

He says a new federal initiative could be transformative for sickle cell patients.

Lakshmanan Krishnamurti. / Yale

Indian-origin physician Lakshmanan Krishnamurti, MD, professor of pediatrics at Yale School of Medicine and chief of pediatric hematology, oncology, and bone marrow transplant at Yale New Haven Children’s Hospital, said a new federal initiative could be transformative for sickle cell patients.

Krishnamurti earned his MBBS from the University of Poona, Armed Forces Medical College, and completed a pediatrics residency at the University of Bombay, India. He told Yale School of Medicine that the program will improve access to costly but potentially curative gene therapies for Medicaid patients in Connecticut.

This post is for paying subscribers only

SUBSCRIBE NOW

Comments

This is a Premium Article, available exclusively to our subscribers.

Read 500+ such News or articles every month by subscribing today!
Monthly

Free

Limited Access

Limited View

Free weekly E-Paper

Subscribe Now
Monthly

$10

Full Access

Unlimited View

Free weekly E-Paper

Free daily newsletter

Subscribe Now
Annual

$50

Full Access

Unlimited View

Free weekly E-Paper

Free daily newsletter

Subscribe Now
Start the conversation

Become a member of New India Abroad to start commenting.

Sign Up Now

Already have an account? Login